VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response-Reference-Cited by-同舟云学术

VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response

Published:2023-12-26 Issue: Volume: Page:
ISSN:1346-4523
Container-title:Journal of Medical Ultrasonics
language:en
Short-container-title:J Med Ultrasonics

Author:

Matono Tomomitsu,Tada Toshifumi,Nishimura Takashi,Takashima Tomoyuki,Aizawa Nobuhiro,Ikeda Naoto,Shiomi Hideyuki,Enomoto Hirayuki,Iijima Hiroko

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10396-023-01398-5.pdf

Reference35 articles.

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.

2. Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76.

3. European Association for the Study of the Liver, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative: Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.

4. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with directacting antiviral agents. Gastroenterology. 2017;153:996–1005.

5. Nahon P, Layese R, Bourcier V, et al. ANRS CO12 CirVir Group Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436–50.